HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification
Yahoo Finance · Jul 2, 2026 · HCM (HCM)
First selective MET inhibitor approved for patients with MET-amplified advanced gastric cancer or gastroesophageal junction adenocarcinoma in ChinaHONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 02, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (NDA) for ORPATHYS® (savolitinib) has been granted conditional approval by the China National Medical Products Administration (“NMPA”) for the treatment of locall
Not investment advice. Cached headline, not a full reprint.